Position
Chief Scientific Officer
Company
BioLoomics
Description
BioLoomics, a biotechnology company targeting peptide-antibody chimeras to specific compartments inside of diseased cells, has announced the appointment of Kurt Gish, Ph.D., as the Chief Scientific Officer. Dr. Gish will focus on building the company’s pipeline of lysosomal targeting ADCs in oncology to overcome the limitations of poor tumor uptake, which hinders safety and efficacy across the ADC market.
FundzWatch™ Score
81
Medium Activity
Executive Insights
Based on hiring dataNew executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months